Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more
Eledon Pharmaceuticals Inc (ELDN) - Net Assets
Latest net assets as of September 2025: $35.36 Million USD
Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has net assets worth $35.36 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($129.86 Million) and total liabilities ($94.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $35.36 Million |
| % of Total Assets | 27.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | -38.02% |
| 10-Year Change | 91.4% |
| Growth Volatility | 581.59 |
Eledon Pharmaceuticals Inc - Net Assets Trend (2012–2024)
This chart illustrates how Eledon Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eledon Pharmaceuticals Inc (2012–2024)
The table below shows the annual net assets of Eledon Pharmaceuticals Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $118.14 Million | +41.62% |
| 2023-12-31 | $83.42 Million | -0.91% |
| 2022-12-31 | $84.18 Million | -48.67% |
| 2021-12-31 | $164.00 Million | -13.96% |
| 2020-12-31 | $190.60 Million | +1913.69% |
| 2019-12-31 | $9.46 Million | -34.69% |
| 2018-12-31 | $14.49 Million | -25.50% |
| 2017-12-31 | $19.45 Million | -27.57% |
| 2016-12-31 | $26.86 Million | -56.49% |
| 2015-12-31 | $61.72 Million | -40.36% |
| 2014-12-31 | $103.50 Million | +287.27% |
| 2013-12-31 | $-55.27 Million | -38.51% |
| 2012-12-31 | $-39.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eledon Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30825600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00K | 0.05% |
| Other Comprehensive Income | $26.00K | 0.02% |
| Other Components | $473.64 Million | 400.91% |
| Total Equity | $118.14 Million | 100.00% |
Eledon Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
POLARIS RENEWABLE ENERGY
F:N4T
|
$156.89 Million |
|
Asia Polymer Corp
TW:1308
|
$156.91 Million |
|
Aten International Co Ltd
TW:6277
|
$156.92 Million |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
$156.94 Million |
|
Jiangsu Daybright Intelligent Electric Co Ltd
SHE:300670
|
$156.79 Million |
|
Indo Thai Securities Limited
NSE:INDOTHAI
|
$156.76 Million |
|
Opus Genetics, Inc.
NASDAQ:IRD
|
$156.71 Million |
|
NICE Holdings Co. Ltd
KO:034310
|
$156.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eledon Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 83,419,000 to 118,140,000, a change of 34,721,000 (41.6%).
- Net loss of 36,184,000 reduced equity.
- New share issuances of 133,307,000 increased equity.
- Other comprehensive income increased equity by 26,000.
- Other factors decreased equity by 62,428,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.18 Million | -30.63% |
| Share Issuances | $133.31 Million | +112.84% |
| Other Comprehensive Income | $26.00K | +0.02% |
| Other Changes | $-62.43 Million | -52.84% |
| Total Change | $- | 41.62% |
Book Value vs Market Value Analysis
This analysis compares Eledon Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-420.88 | $2.88 | x |
| 2013-12-31 | $-582.96 | $2.88 | x |
| 2014-12-31 | $2591.80 | $2.88 | x |
| 2015-12-31 | $444.72 | $2.88 | x |
| 2016-12-31 | $1263.13 | $2.88 | x |
| 2017-12-31 | $74.85 | $2.88 | x |
| 2018-12-31 | $28.97 | $2.88 | x |
| 2019-12-31 | $14.44 | $2.88 | x |
| 2020-12-31 | $131.32 | $2.88 | x |
| 2021-12-31 | $11.07 | $2.88 | x |
| 2022-12-31 | $5.89 | $2.88 | x |
| 2023-12-31 | $3.39 | $2.88 | x |
| 2024-12-31 | $2.43 | $2.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eledon Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.50x
- Recent ROE (-30.63%) is above the historical average (-60.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.66 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.20 Million |
| 2014 | -22.51% | 0.00% | 0.00x | 1.04x | $-33.65 Million |
| 2015 | -73.05% | 0.00% | 0.00x | 1.10x | $-51.26 Million |
| 2016 | -141.33% | 0.00% | 0.00x | 1.11x | $-40.64 Million |
| 2017 | -67.43% | 0.00% | 0.00x | 1.07x | $-15.06 Million |
| 2018 | -97.05% | 0.00% | 0.00x | 1.17x | $-15.51 Million |
| 2019 | -169.16% | 0.00% | 0.00x | 1.15x | $-16.96 Million |
| 2020 | -11.97% | -19009.17% | 0.00x | 1.03x | $-41.87 Million |
| 2021 | -21.04% | -28755.00% | 0.00x | 1.04x | $-50.91 Million |
| 2022 | -104.49% | 0.00% | 0.00x | 1.10x | $-96.38 Million |
| 2023 | -48.34% | 0.00% | 0.00x | 1.51x | $-48.67 Million |
| 2024 | -30.63% | 0.00% | 0.00x | 1.50x | $-48.00 Million |
Industry Comparison
This section compares Eledon Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eledon Pharmaceuticals Inc (ELDN) | $35.36 Million | 0.00% | 2.67x | $156.79 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |